Literature DB >> 18769342

Oncocytoma can be differentiated from its renal cell carcinoma mimics by a panel of markers: an automated tissue microarray study.

Wei Huang1, Kazunori Kanehira, Sally Drew, Thomas Pier.   

Abstract

BACKGROUND: Differentiating oncocytoma from its renal cell carcinoma (RCC) mimics, particularly chromophobe RCC, can be difficult, especially when limited tissue is available for evaluation. This study presents a panel of markers that are readily available, easy to use, and useful for differential diagnoses of renal tumors.
DESIGN: A renal cell neoplasm tissue microarray was constructed including oncocytoma (n=30), chromophobe RCC (n=18), conventional RCC (n=64), papillary RCC (n=50), and benign renal tissues (n=31). CK7, CD10, epithelial membrane antigen, renal cell carcinoma marker (RCCma), vimentin, and endogenous avidin-binding activity (EABA) were studied. An Automated Cellular Imaging System, was used to quantify the staining intensity. RESULT: EABA was positive in 97% of oncocytoma, 26% of conventional RCC and 35% of papillary RCC with granular/eosinophilic (G/E) features and 6% of chromophobe RCC. EABA was negative in RCC without G/E features. Vimentin and RCCma were positive in most RCC with G/E features (conventional, 78% and 71%; and papillary, 85% and 76%, respectively), and negative in oncocytoma. Vimentin was also negative in chromophobe RCC. CK7 was positive in up to 81% of papillary RCC and 63% of chromophobe RCC, and essentially negative in conventional RCC and oncocytoma.
CONCLUSIONS: EABA is an excellent marker for oncocytoma, which can be useful in differentiating oncocytoma from chromophobe RCC. A panel of EABA, vimentin, and RCCma markers can be useful in discerning oncocytoma from RCC with G/E features. Vimentin can be useful in discriminating chromophobe RCC from papillary or conventional RCCs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18769342     DOI: 10.1097/PAI.0b013e318173e79d

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  9 in total

1.  Renal tumors: diagnostic and prognostic biomarkers.

Authors:  Puay Hoon Tan; Liang Cheng; Nathalie Rioux-Leclercq; Maria J Merino; George Netto; Victor E Reuter; Steven S Shen; David J Grignon; Rodolfo Montironi; Lars Egevad; John R Srigley; Brett Delahunt; Holger Moch
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

Review 2.  Percutaneous biopsy for risk stratification of renal masses.

Authors:  Michael L Blute; Anna Drewry; Edwin Jason Abel
Journal:  Ther Adv Urol       Date:  2015-10

Review 3.  Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.

Authors:  Marina O Golovastova; Dmitry O Korolev; Larisa V Tsoy; Vladimir A Varshavsky; Wan-Hai Xu; Andrey Z Vinarov; Evgeni Yu Zernii; Pavel P Philippov; Andrey A Zamyatnin
Journal:  Curr Urol Rep       Date:  2017-01       Impact factor: 3.092

4.  Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo.

Authors:  Jonathan A Ewald; Joshua A Desotelle; Dawn R Church; Bing Yang; Wei Huang; Timo A Laurila; David F Jarrard
Journal:  Prostate       Date:  2012-08-21       Impact factor: 4.104

5.  Endogenous biotin expression in renal and testicular tumours and literature review.

Authors:  Nader Fahmy; Mark Woo; Mona Alameldin; Joe King Lee; Kyle MacDonald; Lee W Goneau; Peter Cadieux; Jeremy Burton; Stephen Pautler
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

6.  The contemporary role of renal mass biopsy in the management of small renal tumors.

Authors:  Amy Lim; Brock O'Neil; Marta E Heilbrun; Christopher Dechet; William T Lowrance
Journal:  Front Oncol       Date:  2012-09-10       Impact factor: 6.244

7.  Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma.

Authors:  Adam Kowalewski; Łukasz Szylberg; Janusz Tyloch; Paulina Antosik; Izabela Neska-Długosz; Łukasz Frąckowski; Dominik Tyloch; Piotr Purpurowicz; Dariusz Grzanka
Journal:  Pathol Oncol Res       Date:  2018-11-22       Impact factor: 3.201

8.  CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.

Authors:  Ariel A Williams; John P T Higgins; Hongjuan Zhao; Börje Ljunberg; James D Brooks
Journal:  BMC Clin Pathol       Date:  2009-11-18

9.  Evaluating prognosis by CK7 differentiating renal cell carcinomas from oncocytomas can be used as a promising tool for optimizing diagnosis strategies.

Authors:  Fuling Ma; Liang Dai; Zhun Wang; Liqun Zhou; Yuanjie Niu; Ning Jiang
Journal:  Oncotarget       Date:  2016-07-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.